Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually measure glucose levels.

Under the terms of the agreement, Senseonics has granted Roche the rights to promote, market and sell the Eversense product line to diabetes clinics and patients in Germany, Italy and the Netherlands.

Tim Goodnow, CEO and president of Senseonics, said: “We are pleased to have Roche as our partner and our distribution agreement represents an important step to enable expanded market access to our product.

“Roche Diabetes Care is ideally suited to market and commercialise the Eversense CGM System. Together with Roche’s market presence, and extensive sales and support network, we aim to deliver a truly innovative continuous, long-term glucose monitoring solution to millions of people with diabetes.”

Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing of Eversense while Roche will be responsible for sales, marketing, customer support and distribution activities in Germany, Italy and the Netherlands.

The distribution agreement may be expanded with additional products and territories in the future, according to Roche.